ABGSC assisted Medivir in raising total proceeds of approximately SEK 225m and strengthening the Company’s institutional shareholder base

On 5 February 2021 Medivir AB (publ) (“Medivir” or the “Company”) announced the preliminary results from its rights issue, raising proceeds of approximately SEK 170m (the “Rights Issue”). The Rights Issue attracted very strong interest and was oversubscribed by 94%. Due to the very strong interest to subscribe for shares in Medivir, the Company exercised an Over-allotment option, directed to the specialist investor Healthinvest Partners AB (“Healthinvest”), raising an additional SEK 25m (the “Over-allotment Option”). In addition, on 7 February 2021 Medivir also announced the intention to carry out a directed issue (the “Directed Issue”) to the specialist investor, and existing owner, LINC AB (“LINC”). The Directed Issue is contingent on approval on an EGM to be held on 11 March 2021. The total proceeds from the Rights Issue, the Over-allotment Option and the Directed Issue will be used for clinical work related to a planned combination study with the Company’s drug candidate MIV-818, preparations for phase II/III in the development of MIV-818 and to cover general and administrative costs. Following the completion of the announced transactions, Medivir’s institutional shareholder base will be strengthened significantly through the Over-allotment Option directed to the specialist investor Healthinvest as well as through the potential Directed Issue to the specialist investor, and existing owner, LINC. ABG Sundal Collier acted as Sole Global Coordinator and financial advisor to Medivir in connection with the transactions.